SCHEMBL15375445

SCHEMBL15375445

CC(C)c1ccccc1OCc1ccccc1C(O)C#N

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NISCH Q9Y2I1 1/20 0.43
SGMS2 Q8NHU3 8/20 0.40
ALDH1A1 P00352 5/20 0.40
LMNA P02545 5/20 0.40
ADRB2 P07550 2/20 0.40
ADRB1 P08588 2/20 0.40
ADRB3 P13945 2/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
KDM4E B2RXH2 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.38
CYP3A4 P08684 1/20 0.38
RECQL P46063 1/20 0.38
GAA P10253 1/20 0.38
FABP4 P15090 1/20 0.37
FABP5 Q01469 1/20 0.37
SLC6A2 P23975 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15375398 0.87 ACHE (0.34) NISCHLMNAKMT2AMEN1CYP1A2
SCHEMBL15375550 0.86 SGMS2 (0.41) NISCHSGMS2ALDH1A1LMNAADRB2
SCHEMBL28038432 0.86 ALOX15 (0.44) SGMS2ALDH1A1LMNAADRB2ADRB1
SCHEMBL15375461 0.86 MAPT (0.46) NISCHSGMS2ALDH1A1LMNAADRB2
SCHEMBL15375387 0.86 GLRA1 (0.37) SGMS2LMNACYP1A2CYP3A4FABP4
SCHEMBL1900216 0.86 ALOX15 (0.44) SGMS2ALDH1A1LMNAADRB2ADRB1
SCHEMBL15375378 0.82 RXRA (0.44) NISCHSGMS2ALDH1A1LMNACYP1A2
SCHEMBL15375379 0.82 SGMS2 (0.38) SGMS2ALDH1A1LMNACYP1A2CYP2C9
SCHEMBL28810581 0.81 RXRA (0.41) ALDH1A1LMNAKMT2AMEN1KDM4E
SCHEMBL15375483 0.81 RXRA (0.41) ALDH1A1LMNAKMT2AMEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2682382-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-23 EP disclosed
EP-2662352-B1 Method for Producing Phenylacetamide Compound SUMITOMO CHEMICAL CO (JP) 2016-11-09 EP disclosed
EP-2397459-B1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL CO (JP) 2015-12-16 EP disclosed
EP-2682382-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2014-01-08 EP disclosed
US-8624062-B2 Method for producing phenylacetamide compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2014-01-07 US disclosed
EP-2662352-A2 Method for Producing Phenylacetamide Compound Sumitomo Chemical Company, Limited (JP) 2013-11-13 EP disclosed
EP-2397459-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND Sumitomo Chemical Company, Limited (JP) 2011-12-21 EP disclosed
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110295035-A1 METHOD FOR PRODUCING PHENYLACETAMIDE COMPOUND MRPL21, AADAC, ARSA NISCH 1639/4885SGMS2 1658/4885ALDH1A1 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.